Xtant Medical (NYSEAMERICAN:XTNT) Stock Passes Above Two Hundred Day Moving Average – Time to Sell?

Posted by Casey Walker on Jul 18th, 2025

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT – Get Free Report)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.53 and traded as high as $0.67. Xtant Medical shares last traded at $0.62, with a volume of 137,562 shares changing hands.

Xtant Medical Trading Up 6.9%

The business has a fifty day moving average of $0.65 and a two-hundred day moving average of $0.53. The firm has a market cap of $86.38 million, a price-to-earnings ratio of -6.89 and a beta of -0.14. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.03 and a current ratio of 2.34.

Hedge Funds Weigh In On Xtant Medical

A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC increased its holdings in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT – Free Report) by 15.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 798,033 shares of the medical device company’s stock after purchasing an additional 103,825 shares during the period. Renaissance Technologies LLC owned approximately 0.57% of Xtant Medical worth $354,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Xtant Medical Company Profile

(Get Free Report)

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.